NetworkNewsBreaks – BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT) Confident in the Future of Bria-IMT Following its Demonstrated Success in Clinical Trials

BriaCell Therapeutics (OTC: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, sees a promising future for its lead product candidate, Bria-IMT. An article discussing the company reads, “The company recently presented promising results for two of its clinical studies (monotherapy and combination study of Bria-IMT with pembrolizumab [KEYTRUDA®; manufactured by Merck & Co., Inc.]) for patients with advanced breast cancer during the 2018 San Antonio Breast Cancer Symposium in Texas (http://nnw.fm/5YriX).  … ‘I am very excited about our data continuing to show robust biological activity of Bria-IMT in advanced breast cancer,’ Dr. Bill Williams, BriaCell’s president & CEO, said of the company’s presentation at the international symposium that attracted over 7,000 academic and private physicians and researchers (http://nnw.fm/Po3A0).  ‘These findings also reinforce our product development strategy for Bria-OTS, BriaCell’s novel off-the-shelf personalized immunotherapy, by showing predictability of the anti-tumor responses in patients using a relatively simple and inexpensive HLA test.’”

To view the full article, visit http://nnw.fm/Tm2FS

About BriaCell

BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with pembrolizumab [Keytruda; manufactured by Merck & Co., Inc.] or ipilimumab [Yervoy; manufactured by Bristol-Myers Squibb Company]. The combination study is listed in ClinicalTrials.gov as NCT03328026. BriaCell is developing Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS, which is expected to cover over 90 percent of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense, and complex manufacturing logistics associated with other personalized immunotherapies. For more information, visit the company’s website at www.BriaCell.com.

More from NetworkNewsBreaks

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]